Traditional risk factors may not be enough when managing cardiovascular disease. Going beyond standard lipid panels may help uncover residual risk for heart attack and stroke.
A patient may have normal LDL-C levels, but still be at risk for adverse events. Inflammatory marker testing may help identify hidden risk for disease, disease presence, and disease activity.
In many patients, the risk of cardiovascular disease may be due to nonlipid factors, like genetics. Quest offers cardiogenetic testing to aid in early diagnosis of affected patients and family members.
Injury, or the infiltration of LDL particles into the arterial wall, is only part of the cardiovascular disease (CVD) story. Inflammation is the other part—and measuring inflammatory biomarkers in patients being treated for elevated LDL-C levels may provide deeper insight to help reduce CVD risk. Learn more in our white paper.
Metabolic syndrome has become increasingly common, and patients who have it are at higher risk of multiple chronic conditions. Cardio IQ® testing options may help you evaluate risk and take action.
Focus on earlier identification of heart failure (HF) risk with actionable testing. The recently updated ACCF/AHA guidelines for the management of HF recommend BNP or NT-proBNP biomarkers, along with early intervention, as an aid for prevention.
Familial hypercholesterolemia (FH) is one of the most common inherited disorders, and yet it is generally underdiagnosed. FH testing provides actionable information that may help lead to earlier treatment.